Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Leerink Partners analyst Michael Cherny upgraded the rating for CVS Health Corporation (NYSE:CVS) from Market Perform to Outperform and raised the price target from $55 to $75. CVS Health shares closed at $63.22 on Wednesday. See how other analysts view this stock.
- Barclays analyst Duffy Fischer upgraded DuPont de Nemours, Inc. (NYSE:DD) from Underweight to Equal-Weight and boosted the price target from $85 to $89. DuPont shares closed at $81.76 on Wednesday. See how other analysts view this stock.
- Wells Fargo analyst Mohit Bansal upgraded the rating for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) from Equal-Weight to Overweight and raised the price target from $130 to $170. Jazz Pharmaceuticals shares closed at $135.44 on Wednesday. See how other analysts view this stock.
- UBS analyst Matthew Weston upgraded AstraZeneca PLC (NASDAQ:AZN) from Neutral to Buy. AstraZeneca shares closed at $74.43 on Wednesday. See how other analysts view this stock.
- Morgan Stanley analyst Jeffrey Hung upgraded the rating for Cytokinetics, Incorporated (NASDAQ:CYTK) from Equal-Weight to Overweight but lowered the price target from $70 to $67. Cytokinetics shares closed at $42.18 on Wednesday. See how other analysts view this stock.
Considering buying AZN stock? Here’s what analysts think:
Read This Next:
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
